We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
STELARA (Janssen-Cilag Pty Ltd)
Product name
STELARA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
215 working days (255)
Active ingredients
ustekinumab
Registration type
EOI
Indication
Plaque Psoriasis - Paediatric population, 6 years and older
STELARA (solution for injection) is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from 6 years of age who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.